Here is the design of a clinical trial:

Official Title: Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial

Included conditions:
- Heart Arrest
- Out-Of-Hospital Cardiac Arrest
- Systemic Inflammatory Response Syndrome

Study Armgroups:
- {'label': 'Tocilizumab', 'type': 'ACTIVE_COMPARATOR', 'description': 'A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.', 'interventionNames': ['Drug: Tocilizumab 20 Mg/mL Intravenous Solution']}
- {'label': 'Isotonic saline', 'type': 'PLACEBO_COMPARATOR', 'description': 'A one hour infusion of isotonic saline', 'interventionNames': ['Drug: isotonic saline']}

Interventions:
- {'type': 'DRUG', 'name': 'Tocilizumab 20 Mg/mL Intravenous Solution', 'description': 'Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion', 'armGroupLabels': ['Tocilizumab'], 'otherNames': ['RoActemra']}
- {'type': 'DRUG', 'name': 'isotonic saline', 'description': 'A one hour infusion of 100mL isotonic saline', 'armGroupLabels': ['Isotonic saline'], 'otherNames': ['Placebo']}

Primary Outcomes:
- {'measure': 'Concentration of hsCRP', 'description': 'high sensitivity C-reactive protein', 'timeFrame': 'Daily measurements from admission to 72 hours after admission.'}

Please estimate the sample size based on the assumption: 
The trial assumes a significance level (α) of 0.05, a power of 0.81, and accounts for an 8% mortality rate within the first 3 days and potential missing blood samples.
Sample size {14}
        The trial is powered at the primary endpoint. A previous trial has shown an effect of tocilizumab on hsCRP in NSTEMI patients [21]. That trial demonstrated a median area under the hsCRP curve of 2.0âmg/L/h in patients receiving tocilizumab compared to 4.2âmg/L/h in patients receiving placebo, i.e., a reduction of 52%. However, the systemic inflammatory response in a NSTEMI population will be limited compared to an OHCA population. For example, hsCRP levels in NSTEMI patients have been reported at approximately 2â6âmg/L [21], whereas CRP levels in OHCA patients have been reported at approximately 100â250âmg/L after 48â72âh [25].
        As no previous data exists regarding the effect of tocilizumab on hsCRP over time, we chose to power the present trial towards a single hsCRP measurement drawn 48âh after admission. In 140 resuscitated OHCA patients from our institution, the mean hsCRP level after 48âh was 179âÂ±â75âmg/L (unpublished data). We assumed that tocilicumab treatment would reduce the hsCRP level by 30%. Assuming an Î±-level of 0.05, the trial would achieve a power of 0.81, if 64 patients were included. However, taking mortality within the first 3âdays (estimated at 8% [26]) as well as blood samples missing for other reasons into account, we aimed to include 80 patients.